Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIL-21 vs Dacarbazine in Metastatic Melanoma
NCT01152788Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2010
- Primary completion
- Nov 2014
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of recombinant human interleukin 21 in melanoma (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Progression Free Survival at 22 months. Started Aug 2010; status: completed.
02
Drugs
recombinant human interleukin 21
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01152788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01152788.